Docmode Health

Why is Docmode Health Technologies Ltd falling/rising?

As of 19-Jul, the stock price of Docmode Health Technologies Ltd is stable at 37.50, but it has decreased by 7.41% over the past month and 47.41% year-to-date, underperforming compared to the Sensex. Despite some positive indicators like increased investor participation and sector outperformance today, the stock's longer-term moving averages suggest a bearish trend.

As of 19-Jul, the stock price of Docmode Health Technologies Ltd is currently stable at 37.50, showing no change (0.00%). However, when examining the stock's performance over various periods, it is evident that the stock has faced significant challenges. Over the past month, the stock has decreased by 7.41%, and year-to-date, it has fallen by 47.41%. In contrast, the Sensex has shown a modest increase of 1.03% over the same month and a decline of only 6.87% year-to-date, indicating that Docmode Health Technologies Ltd has underperformed relative to the broader market.<BR><BR>Despite the current price stability, there are some positive indicators. The stock has outperformed its sector by 0.59% today, and there has been a notable increase in investor participation, with delivery volume rising by 150% compared to the 5-day average. This suggests a growing interest among investors, which could potentially support the stock price in the near future.<BR><BR>However, the stock's moving averages indicate that while it is currently higher than the 5-day moving average, it remains lower than the 20-day, 50-day, 100-day, and 200-day moving averages. This could imply a bearish trend in the longer term. Overall, while there are signs of increased trading activity and sector outperformance today, the significant declines over the past month and year indicate that the stock is facing ongoing challenges.

Which are the latest news on Docmode Health?

What does Docmode Health do?

Docmode Health Technologies Ltd is a micro-cap healthcare technology company focused on transforming medical education, research, and practice. It was incorporated in 2017 and became public in 2023, with a market cap of INR 14 Cr and currently lacks available revenue and profit data.

Overview: <BR>Docmode Health Technologies Ltd is a pioneering healthcare technology company that is transforming the landscape of medical education, research, and practice, operating within the hospital industry and classified as a micro-cap company.<BR><BR>History: <BR>Docmode Health Technologies Limited was incorporated on July 17, 2017, as a private limited company and was subsequently converted into a public limited company effective January 2, 2023. Revenue and profit data for the latest quarter are not available.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 14 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 147 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.59 <BR>Return on Equity: -24.30% <BR>Price-to-Book: 1.65<BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

How big is Docmode Health?

As of 10th June, Docmode Health Technologies Ltd has a market capitalization of 14.00 Cr, classifying it as a Micro Cap company, with no available financial data for Net Sales or Net Profit for the latest four quarters. The balance sheet as of March 2025 shows Shareholder's Funds of 8.35 Cr and Total Assets of 39.06 Cr.

As of 10th June, <BR><BR>Market Cap: Docmode Health Technologies Ltd has a market capitalization of 14.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales or Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2025, with Shareholder's Funds amounting to 8.35 Cr and Total Assets valued at 39.06 Cr.

Who are the peers of the Docmode Health?

Docmode Health's peers include Maitreya Medica, Sangani Hospital, Aatmaj Health, and others, with most showing below average management risk and growth. Aatmaj Health leads in 1-year returns at 1.59%, while Docmode Health has a return of -34.33%.

Peers: The peers of Docmode Health are Maitreya Medica., Sangani Hospital, Aatmaj Health, Nidan Laborator., Global Longlife, KK Shah Hospital, Broach Lifecare, Soni Medicare, Shanmuga Hos., and Fortis Malar.<BR><BR>Quality Snapshot: Below Average management risk is observed at Maitreya Medica., Sangani Hospital, Nidan Laborator., Docmode Health, KK Shah Hospital, Broach Lifecare, Soni Medicare, and Fortis Malar, while Average management risk is found at Aatmaj Health and Shanmuga Hos. Excellent growth is noted at Sangani Hospital, while Below Average growth is seen at Maitreya Medica., Aatmaj Health, Nidan Laborator., Docmode Health, Global Longlife, KK Shah Hospital, Broach Lifecare, Soni Medicare, and Fortis Malar. Good capital structure is present at Sangani Hospital, Aatmaj Health, KK Shah Hospital, Broach Lifecare, and Shanmuga Hos., while Below Average capital structure is found at Maitreya Medica., Nidan Laborator., Docmode Health, Global Longlife, Soni Medicare, and Fortis Malar.<BR><BR>Return Snapshot: Aatmaj Health has the highest 1-year return at 1.59%, while Maitreya Medica. has the lowest at -45.96%. Docmode Health's 1-year return of -34.33% is better than Maitreya Medica.'s but worse than Aatmaj Health's. Additionally, the six-month return is negative for Maitreya Medica., Sangani Hospital, Aatmaj Health, Nidan Laborator., Docmode Health, and Fortis Malar.

How has been the historical performance of Docmode Health?

Docmode Health has experienced significant sales growth from 12.42 Cr in March 2022 to 41.77 Cr in March 2025, but rising expenditures have led to negative operating profit and losses in profit before and after tax, with EPS dropping to -6.46. Total assets and liabilities have increased to 39.06 Cr by March 2025, while cash flow remains tight.

Answer:<BR>The historical performance of Docmode Health shows a fluctuating trend in key financial metrics over the past four fiscal years.<BR><BR>Breakdown:<BR>Docmode Health's net sales have increased from 12.42 Cr in March 2022 to 41.77 Cr in March 2025, indicating a strong growth trajectory. However, the total expenditure has also risen significantly, from 10.54 Cr in March 2022 to 42.45 Cr in March 2025, leading to an operating profit (PBDIT) that turned negative at -0.68 Cr in March 2025, down from a positive 3.75 Cr in March 2023. Consequently, the profit before tax has declined sharply to -1.97 Cr in March 2025, compared to 2.69 Cr in March 2023. The profit after tax mirrored this decline, falling to -2.03 Cr in March 2025 from 1.95 Cr in March 2023. The company's earnings per share (EPS) also reflect this downturn, dropping to -6.46 in March 2025 from 8.52 in March 2023. On the balance sheet, total assets have increased from 10.01 Cr in March 2022 to 39.06 Cr in March 2025, while total liabilities have also risen from 10.01 Cr to 39.06 Cr in the same period. Cash flow from operating activities improved to 4.00 Cr in March 2024, but the overall cash flow situation remains tight with a closing cash equivalent of 3.00 Cr in March 2024.

Who are the top shareholders of the Docmode Health?

The top shareholders of Docmode Health include Paulson Paul Thazhathedath, who holds 23.71%, and individual investors who collectively own 48.97%. There are no mutual funds or foreign institutional investors involved, and pledged promoter holdings are at 61.1641%.

The top shareholders of Docmode Health primarily consist of non-institutional investors. The promoter with the highest holding is Paulson Paul Thazhathedath, who owns 23.71% of the company. Additionally, individual investors collectively hold 48.97% of the shares. There are no mutual funds or foreign institutional investors currently holding shares in the company. The pledged promoter holdings stand at 61.1641%.

Is Docmode Health overvalued or undervalued?

As of June 2, 2025, Docmode Health is classified as risky and overvalued, with a PE ratio of -10.42 and a year-to-date return of -23.83%, significantly underperforming compared to its peers and the Sensex.

As of 2 June 2025, the valuation grade for Docmode Health has moved from does not qualify to risky. The company is currently assessed as overvalued. Key ratios indicate significant financial distress, with a PE ratio of -10.42, an EV to EBIT of -27.08, and a ROE of -19.55%. <BR><BR>In comparison to its peers, Docmode Health's valuation metrics are starkly unfavorable; for instance, Veranda Learning, also classified as risky, has a PE ratio of 165.27, while Shanti Educational Initiatives Ltd. is deemed very expensive with a PE ratio of 199.65. The recent stock performance shows a significant decline, with a year-to-date return of -23.83%, contrasting sharply with the Sensex's gain of 6.24% during the same period, further reinforcing the overvaluation narrative.

What is the technical trend for Docmode Health?

As of June 2, 2025, Docmode Health's trend has shifted to mildly bearish due to daily moving averages indicating bearish momentum, despite some underlying strength from weekly MACD and a neutral outlook from Dow Theory.

As of 2 June 2025, the technical trend for Docmode Health has changed from mildly bullish to mildly bearish. The current stance is mildly bearish, primarily driven by the daily moving averages indicating bearish momentum. The weekly MACD remains mildly bullish, suggesting some underlying strength, but the overall trend is tempered by the daily indicators. The RSI shows no signal across both weekly and monthly time frames, indicating a lack of momentum. Additionally, the Dow Theory shows no trend in both weekly and monthly perspectives, further supporting a neutral outlook. Overall, while there are some bullish signals in the weekly indicators, the prevailing daily bearish trend suggests caution.

When is the next results date for Docmode Health?

No Upcoming Board Meetings

Has Docmode Health declared dividend?

No Dividend History Available